Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Soteria Biotherapeutics
San Francisco, California, United States
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
Soteria Biotherapeutics is developing a pipeline of switchable bispecific T-cell engagers using its T-LITE platform, currently in preclinical R&D with in vitro and mouse model data supporting controlled T-cell activation for safer, more effective treatment of solid tumors and B-cell malignancies[2][6][9].
- Therapeutic areas
- Oncology
- Modalities
- Bispecific monoclonal antibodySmall moleculeMonoclonal antibody
- Industry
- Biotech
02
Partnerships
Roche Venture Fund (investor)Novartis Venture Fund (investor)5AM Ventures (investor)Alexandria Venture Investments (investor)M Ventures (investor)
Beyond the preview
Go deeper on Soteria Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Soteria Biotherapeutics.